Combining PIM‐2 and PARP1 Inhibitors Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells through NKG2D Binding
Advanced Science · 2025
DOI: 10.1002/advs.202502448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Zhaoyun Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tianjin Medical University General Hospital, 154 Anshan Street, Tianjin, 300052, P. R. China. Hauptthemen laut MEDLINE: Killer Cells, Natural, Multiple Myeloma, NK Cell Lectin-Like Receptor Subfamily K, Poly (ADP-Ribose) Polymerase-1. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key research and development projects of the Ministry of Science and Technology, National Natural Science Foundation Project, Tianjin Municipal Natural Science Foundation.
Abstract (Originalsprache)
While immunogenic death in tumor cells activates specific anti‐tumor T cells, the activation of non‐specific natural killer (NK) cells through tumor interactions remains underexplored. This study investigates how inducing DNA damage in multiple myeloma (MM) cells leads to MICA overexpression, facilitating NKG2D binding on NK cells.We analyzed the relationship between PIM‐2, PARP1, and MM prognosis using public data and clinical samples. An in vitro co‐culture of MM and NK cells assessed the effects of SMI‐16a (PIM‐2 inhibitor) and ABT888 (PARP1 inhibitor) on tumor proliferation and apoptosis, focusing on DNA damage, MICA expression, and NK cell functionality. An NSG mouse model evaluated the combined effects on tumor growth and NK cell activity.The combination significantly increased DNA damage, marked by elevated pH2AX, and enhanced NK cell functional markers, including perforin and granzyme B. Increased DNA damage correlated with heightened MICA expression, activating NK cells via the NKG2D/MICA signaling pathway. PIM‐2 and PARP1 inhibitors synergistically induce MICA expression on MM cells, enhancing NK cell activation through NKG2D binding, offering a promising therapeutic strategy for MM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Tianjin Medical University General Hospital, 154 Anshan Street, Tianjin, 300052, P. R. China.
- Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin, 300052, P. R. China.
- Tianjin Institute of Hematology, Tianjin, 300052, P. R. China.
- Department of Nephrology, Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, 323000, P. R. China.
- State Key Laboratory of Experimental Hematology, Tianjin, P. R. China.
ORCID-Profile: Rong Fu
Förderung
- Key research and development projects of the Ministry of Science and Technology
- National Natural Science Foundation Project
- Tianjin Municipal Natural Science Foundation
- Tianjin Science and Technology Planning Project
- Tianjin Municipal Health Commission Project
Zitieren
APA
Liu, Z., Lei, W., Liu, X., Liu, H., Ding, K., Song, J., & Fu, R. (2025). Combining PIM‐2 and PARP1 Inhibitors Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells through NKG2D Binding. Advanced Science. https://doi.org/10.1002/advs.202502448
Vancouver
Liu Z, Lei W, Liu X, Liu H, Ding K, Song J, et al. Combining PIM‐2 and PARP1 Inhibitors Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells through NKG2D Binding. Advanced Science. 2025. doi:10.1002/advs.202502448
BibTeX
@article{Liu2025,
author = {Liu, Zhaoyun and Lei, Wenhui and Liu, Xiaohan and Liu, Hui and Ding, Kai and Song, Jia and Fu, Rong},
title = {Combining PIM‐2 and PARP1 Inhibitors Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells through NKG2D Binding},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202502448}
}
EUVIMED